GHARAMAThe economics of health. The evidence for change.
Health costs. Clear evidence. Better decisions.

What does it cost to live with illness?

Gharama brings health-financing data, research and lived costs together to make the financial burden of chronic illness visible — and turn that evidence into better public health policy.

Healthcare spending in context
24.25%

of Kenya's current health expenditure came from out-of-pocket payments in 2023.

Source: WHO health expenditure data
Who pays directly for healthcare?Share of national health spending
0%100%
WHO / World Bank · latest year available for each country · select a bar for details
What is Gharama?

From the price of care to the policies that change it.

GHARAMA examines how healthcare is financed and what people pay for long-term treatment. Our focus is hypertension, diabetes and heart failure.

Explore published country indicators, understand their limits, and investigate interventions such as medicine subsidies and improved outpatient coverage. Policy scenarios are illustrative, not claims of proven impact.

—Countries and global aggregate listed
—Observations with a reported year
3Chronic conditions explored in policy analysis
Start here

Explore the evidence.

Compare countries, examine policy options or calculate personal expenses.

01 / Explore

Compare health spending

See how much healthcare expenditure is paid directly by households across countries.

02 / Policy

From evidence to action

Identify policy questions, intervention options and measurable outcomes for chronic illness.

03 / People

Understand personal costs

Calculate medicine, transport, visits, lost income and other household expenses.

01 / Explore the evidence

What households pay.

Compare out-of-pocket payments as a share of all current health expenditure. These are health-system indicators, not disease-specific treatment costs.

Out-of-pocket share of current health expenditure

Country comparison

Bars show reported observations from different years. They should not be interpreted as a single-year ranking. Countries without a verified value in this dataset are not plotted.

Kenya
24.25%
Reported 2023
How to interpret this

This is a share of total health spending, not the percentage of an individual patient's income.

Important distinction

National out-of-pocket spending cannot establish what a patient with diabetes or hypertension pays. Disease-level research is needed for that.

See all available observations
CountryOut-of-pocket shareYear
Historical perspective · Published data

How has household-financed spending changed?

Select a country in Explore, then load its reported annual series from the World Bank. The years and values below are reported figures, not projections.

Select a country and load its history (internet required)

02 / The purpose of Gharama

From evidence to better policy.

Understand what a statistic can tell us, what it cannot, and how public health interventions could be designed and evaluated.

01 / What we know

A national financing indicator

02 / What we need to investigate

03 / Potential policy intervention

04 / How to evaluate impact

Measure outcomes, not intentions

05 / Policy design studio

Turn a promising idea into a testable intervention.

Choose a policy approach. Gharama outlines the delivery mechanism, implementation risks, equity considerations and evidence needed before a recommendation can be made.

How it could work

Who may benefit

Implementation challenges

Evaluation design

Evidence gap to close

06 / Scenario explorer

What might a subsidy change?

A transparent arithmetic illustration, not a forecast or measured intervention effect. Enter your own assumptions; no national spending figure is used to infer a patient's treatment cost.

Illustrative patient savings per person—
Illustrative total subsidy cost—

Assumes 100% uptake, fixed prices, full subsidy delivery and no administration costs, behavioural changes or supply constraints. Does not estimate health outcomes or cost-effectiveness.

Evidence library · Published guidance

What does the research support?

Condition-specific, linked guidance. This is clinical and implementation evidence—not proof that a particular financing intervention will save money in your selected country.

Policy translation

A research plan you can use.

Turn a policy idea into a testable question with an implementation pathway, evaluation design, safeguards and the evidence still needed.

Monitoring & evaluation

How would we know it worked?

Suggested indicators for a pilot. Baselines and targets must be established locally, not inferred from national expenditure shares.

Interpretation safeguard. National out-of-pocket spending share is a system-wide financing indicator. It does not reveal household income burden, disease-specific treatment costs, adherence, or the effect of a proposed policy. Gharama does not claim otherwise.
09 / Research evidence to action

What published guidance supports—and what still needs testing.

A carefully scoped evidence register. Clinical and implementation guidance is not proof that a subsidy saves money or improves outcomes in a particular country.

FocusPublished sourceWhat it supportsWhat it cannot establish
HypertensionWHO pharmacological treatment guideline (2021)Evidence-based treatment approaches and follow-up recommendationsLocal medication prices or effects of a proposed subsidy
Primary care deliveryWHO HEARTS risk-based CVD management (2020)A framework for strengthening cardiovascular care in primary health systemsCost-effectiveness in a specific setting without evaluation
Medicine accessWHO HEARTS essential medicines and technologyProcurement, distribution and medicine supply management considerationsActual retail prices, stock-out rates or patient savings
Financial protectionWHO / World Bank national health accountsShare of national current health expenditure paid directly by householdsIndividual financial hardship or condition-specific costs
Research gap: Before making country-specific claims, Gharama needs local medicine prices, disease-specific household spending, benefit coverage and measured outcomes. These are not substituted with synthetic observations.
08 / From analysis to action

Policy implementation workbench

Build an explicit policy hypothesis, test the budget assumptions and identify what must be measured before recommending scale-up. Figures below are user-defined scenarios, never observed programme effects.

A / Intervention readiness

What would it take to implement this?

Check which essential prerequisites are already in place. This is a planning checklist, not an independently assessed country score.

0 of 6

B / Budget sensitivity

How sensitive is the proposal?

Uses your existing scenario assumptions. Change the uptake rate and administration overhead to examine programme expenditure.

All amounts are in the unspecified currency entered in the policy scenario. Excludes behavioural changes, clinical effects, price changes and other programme costs.

C / Evaluation blueprint

What evidence would change a policy decision?

QuestionIndicatorSuggested sourceInterpretation
A national out-of-pocket expenditure share cannot establish whether an intervention works for a specific disease. Local baseline, a credible comparison and follow-up are needed to estimate impact.
03 / Individual financial burden

What does care cost you?

A private, on-device calculator for monthly healthcare expenses. Your entries are not uploaded or stored on a server.

Your monthly costs
Estimated monthly financial burden
KES 0

Direct expenses + lost income − reimbursements

Enter your expenses to begin.
What this means

This is a personal estimate, not a clinical or economic diagnosis. It excludes costs you have not entered and should not be compared directly with national out-of-pocket expenditure shares.

04 / Transparency

Where the evidence comes from.

Good policy begins with knowing what the data actually measure. Gharama distinguishes published statistics, patient estimates and intervention hypotheses.

Evidence status · November 2026. Embedded country observations are a curated reference snapshot and may be superseded by newer official releases. Use “Check for newer figures” to look for more recent published data. Newly retrieved figures are labelled for this session; the stored data are never presented as live data. Country-level expenditure shares cannot be used as disease-specific patient costs.
Current public datasets

World Bank · WHO health expenditure data

Out-of-pocket expenditure (% of current health expenditure), indicator SH.XPD.OOPC.CH.ZS. The dataset embedded here is a curated snapshot with source years shown per observation.

View the official indicator ↗

WHO Global Health Expenditure Database

Underlying international health-expenditure accounting framework and country reporting.

View WHO database ↗

Latest published figures

Check whether newer country figures are available. The figures already displayed remain available without an internet connection.

View data source ↗

Research integrity

What Gharama does not claim

A national out-of-pocket share is not a measure of catastrophic health expenditure, treatment affordability, medicine prices, or the household cost of any specific disease.

No patient records, insurer claims or hospital pricing feeds are currently connected. No simulated patient data are presented as observations. Policy insights are structured hypotheses, not causal findings.

Next evidence layers

Peer-reviewed cost-of-illness studies, facility tariffs, medicine prices, insurance benefit schedules, household surveys and consented patient-reported costs. Each will need dataset-level citations, licensing checks and a clear methodology before publication.

The included figures are a dated reference snapshot. Check individual observations against the official source before citing them in academic or policy work. Online updates depend on connectivity.